Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...

The latest investment will help drive expansion and accelerate research & development to introduce new and novel ingredients to the market.

The $30 million in new investment will fuel expansion and accelerate R&D project execution. This funding round opens up an opportunity to explore different ways to meet...

A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors. His experience of successfully managing several...

Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...

The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to...

Enterome, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered...

LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...